• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: Streamex Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    1/20/26 5:15:25 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $STEX alert in real time by email
    true 0001530766 0001530766 2025-09-05 2025-09-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K/A

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): September 5, 2025

     

    STREAMEX CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38659   26-4333375
    (State or other jurisdiction   (Commission   (IRS Employer
    of incorporation)   File Number)   Identification No.)

     

    2431 Aloma Avenue, Suite 243

    Winter Park, Florida 32792

    (Address of principal executive offices)

    90025

    (Zip Code)

     

    (203) 409-5444

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of exchange on which registered
    Common Stock, par value $0.001 per share   STEX   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

      

    Explanatory Note

     

    This Current Report on Form 8-K/A (the “Amendment No. 1”) is being filed solely to amend Streamex Corp.’ (the “Company”) Current Report on Form 8-K filed on September 5, 2025 (the “Original 8-K”) to correct the Company’s disclosure regarding the approval status of Proposal 6 presented at the Company’s September 5, 2025, Special Meeting of Stockholders. Except as set forth herein, this Amendment No. 1 does not amend, update or otherwise revise any other information contained in the Original 8-K.

     

     

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders

     

    This Amendment No. 1 amends the Original 8-K by the Company to correct the Company’s prior disclosure regarding the results of the stockholder vote at the Special Meeting of Stockholders held on September 5, 2025 (the “Special Meeting”).

     

    At the Special Meeting, Proposal 6 sought approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”), as amended, to classify the board of directors of the Company (the “Board”) into three classes with staggered three-year terms (the “Classified Board Proposal”). As reported in the Original 8-K, there were 15,424,979 votes “for,” 1,009,783 votes “against,” 203,852 abstentions and 3,483,433 broker non-votes with respect to the Classified Board Proposal. The Company has subsequently determined that, based on the voting power entitled to vote as of the July 30, 2025 record date for the Special Meeting, the Classified Board Proposal did not receive the affirmative vote of a majority of the outstanding voting power entitled to vote thereon, as required by Section 242 of the Delaware General Corporation Law. Notwithstanding that shortfall, the Company filed an amendment to the Company’s Certificate of Incorporation reflecting adoption of the Classified Board Proposal with the Delaware Secretary of State on November 19, 2025 and thereafter conducted its December 30, 2025 Annual Meeting of Stockholders in accordance with the Classified Board Proposal.

     

    In light of the foregoing, the Board has determined that:

     

    ●The Classified Board Proposal was not duly adopted and is of no force or effect.

     

    ●Effective immediately, the Company will cease relying on the purported classified structure and will operate under the prior structure, under which all directors serve until the next annual meeting of stockholders and until their successors are duly elected and qualified, and are generally removable with or without cause pursuant to DGCL § 141(k).

     

    ●At the December 30, 2025 Annual Meeting of Stockholders, stockholders validly elected Morgan Lekstrom and Karl Henry McPhie. Those directors will serve until the next annual meeting and until their successors are duly elected and qualified. The other incumbent directors, Kevin Gopaul and Donald Browne, were not submitted for election at that meeting and will continue as holdover directors until their successors are duly elected and qualified.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: January 20, 2026

     

      STREAMEX CORP.
         
      By: /s/ Karl Henry McPhie
      Name: Karl Henry McPhie
      Title: Chief Executive Officer

     

     

    Get the next $STEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STEX

    DatePrice TargetRatingAnalyst
    11/25/2025$12.00Buy
    Needham
    More analyst ratings

    $STEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lekstrom Morgan Lee bought $25,060 worth of shares (7,000 units at $3.58) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    11/21/25 12:44:17 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Streamex Exchange Corporation with a new price target

    Needham initiated coverage of Streamex Exchange Corporation with a rating of Buy and set a new price target of $12.00

    11/25/25 7:59:34 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gopaul Kevin Roy was granted 100,000 shares (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    1/7/26 5:05:15 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Gopaul Kevin Roy

    3 - Streamex Corp. (0001530766) (Issuer)

    12/11/25 5:15:26 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CFO Groenewald Ferdinand was granted 60,000 shares, increasing direct ownership by 26% to 295,000 units (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    11/21/25 4:35:48 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Streamex Corp. (NASDAQ: STEX) Announces Issuance of Prepayment Notice for Previously Announced Convertible Debenture Financing & Notice of Termination for Standby Equity Purchase Agreement

    WINTER PARK, Fla., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization of commodity assets, today announced that it has delivered an optional prepayment notice to the holder of its Secured Convertible Debentures, YA II PN, LTD., a Cayman Islands exempt limited company ("Yorkville" or "Holder"). It has also issued notice to cancel the Standby Equity Purchase Agreement (the "SEPA") previously entered into with Yorkville. Prepayment Notice for Secured Convertible Debentures As previously disclosed, the Company has outstanding Secured Convertible Debentures dated November 4, 2025, and December 17, 2025, wi

    1/23/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Announces Pricing of $35 Million Public Offering

    WINTER PARK, Fla., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization of real-world assets and commodity-backed stablecoins, including GLDY, today announced the pricing of its previously announced underwritten public offering of 11,666,667 shares of common stock at a public offering price of $3.00 per share. The offering is expected to close on or around January 26, 2026, subject to customary closing conditions. The gross proceeds from the offering, before deducting underwriter discounts and commissions and other estimated offering expenses are expected to be approximately $35 million. Streamex intends

    1/22/26 9:03:32 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Announces Proposed Public Offering

    WINTER PARK, Fla., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization of real-world assets and commodity-backed stablecoins, including GLDY, today announced its intention to offer shares of common stock through an underwritten public offering. All of the shares of common stock are being offered by the Company. The completion of the offering remains subject to market conditions, with no assurance regarding its timing, size, or terms. The Company intends to use the net proceeds from the offering to repay prior indebtedness in accordance with our financing strategy, and for working capital and general corp

    1/22/26 5:21:30 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    SEC Filings

    View All

    SEC Form 424B5 filed by Streamex Corp.

    424B5 - Streamex Corp. (0001530766) (Filer)

    1/22/26 5:18:02 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: Streamex Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K/A - Streamex Corp. (0001530766) (Filer)

    1/20/26 5:15:25 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Streamex Corp. (0001530766) (Filer)

    12/30/25 6:55:07 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Financials

    Live finance-specific insights

    View All

    Streamex Corp. (NASDAQ: STEX) Acquires 9.9% Strategic Equity Stake in Royalty and Streaming Firm Empress Royalty Corp. Through a Premium Priced Share-for-Share Transaction at US$5.00 STEX with a Leading Institutional Investment Firm

    LOS ANGELES, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and real-world asset infrastructure, today announced that it has acquired a 9.9% equity interest in Empress Royalty Corp. ("Empress") (TSXV:EMPR) through a strategic share purchase from Terra Capital Natural Resources Fund Pty Ltd. ("Terra Capital"), a prominent institutional investor. Under the executed Share Purchase Agreement, Streamex acquired 12,671,297 common shares of Empress in exchange for 2,443,750 restricted common shares of Streamex at a US$5.00 STEX share price, representing a premium to the current market price of STEX and an

    12/11/25 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Announces Launch of $100,000,000 USD GLDY Pre-Sale – A Gold-Backed Yield Generating Stablecoin Offering Institutional Yield on Physical Gold Bullion

    The launch of Streamex's $100 million USD GLDY pre-sale marks a historic opportunity for gold investors. Investing in gold is no longer just a static store of value, Streamex, through GLDY has created a yield-generating, institutional grade asset designed to offer both spot gold exposure and yield paid in additional ounces of physical gold bullion.  Key Highlights Gold Price Exposure and Gold-Denominated Distributions: GLDY is designed to combine audited physical bullion holdings with yield from institutionally managed gold leases sourced through Monetary Metals. GLDY seeks to provide exposure to the price of gold while targeting periodic distributions paid in additional ounces of gold.Rev

    11/10/25 8:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Leadership Updates

    Live Leadership Updates

    View All

    Streamex Corp. (NASDAQ: STEX) Joins Solana Policy Institute in the Project Open Coalition to Advance Regulated On-Chain Trading of Real-World Assets, Including GLDY

    LOS ANGELES, Dec. 10, 2025 (GLOBE NEWSWIRE) --  Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization of real-world assets, today announced it has joined Project Open, a landmark initiative working to establish a regulated framework for the issuance and trading of securities on public blockchains. The effort aims to unlock billions in traditional asset value through 24/7 trading, instant settlement, lower costs, and enhanced transparency for all real-world assets, while keeping the United States competitive in financial innovation. Streamex joins Solana Policy Institute united to drive the next era of compliant digital market infrastructur

    12/10/25 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Announces Appointment of Kevin Gopaul, Global Financial Executive and ETF Pioneer to Its Board of Directors

    LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today announced the appointment of Kevin Gopaul, global financial executive and pioneering leader in the exchange-traded fund (ETF) industry, to its Board of Directors, effective immediately. Kevin brings more than 25 years of global asset management and capital markets experience, including senior leadership roles as Global Head of ETFs, Chief Investment Officer, and Canadian CEO at BMO Global Asset Management, where he helped architect and scale the firm's $100 billion ETF franchise. He currently serves

    11/18/25 8:09:24 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care